BioPharm challenges cleanroom paradigm

BioPharm International’s August 1, 2011 article challenged a long-standing assumption in biopharmaceutical plant design: that broader cleanroom controls are always the main safeguard for bulk drug-substance manufacturing. The authors — Jeff Johnson, Scott Probst, Tim Palberg, Paul Gil, Matt Kennedy, Joe Rogalewicz, Ken Green and Simon Chalk — argued that newer equipment and process designs justify a more targeted approach. They wrote that environmental controls should be driven by where product is actually exposed, how operators interact with equipment and where transfers occur, rather than by room classification alone. ### What exactly is being challenged? The 2011 BioPharm article said the “traditional cleanroom paradigm” for bulk biopharmaceutical drug-substance manufacturing deserved re-examination because manufacturing technology had changed. The authors framed the issue as one of environmental control strategy, not abandonment of contamination control. They argued that advances in closed systems and process equipment could reduce reliance on blanket room-level measures in some bulk operations. (biopharminternational.com) The article focused on bulk drug-substance manufacturing, not every sterile process. That distinction matters because some operations involve different exposure risks than final aseptic filling, where regulators have long imposed tighter environmental expectations. FDA’s aseptic-processing guidance addresses sterile drug and biological products made using aseptic processing, while U.S. CGMP rules require buildings and facilities to be designed to prevent contamination and mixups. (biopharminternational.com) ### If not blanket room controls, what do the authors want companies to focus on? The BioPharm authors said manufacturers should concentrate controls on the places where contamination risk is most direct: open product exposure, equipment closure, operator interventions and material-transfer points. Their argument was that contamination risk is not evenly distributed across an entire suite, and that design should reflect that. (fda.gov) That approach lines up with later regulatory language that emphasizes contamination-control strategy and quality risk management. The European Medicines Agency has said revised Annex 1 introduced concepts including contamination control strategy, and a 2015 EMA/PIC/S concept paper said Annex 1 was being revised to reflect new technology and clarify older guidance. ### Does this mean cleanrooms no longer matter? (biopharminternational.com) FDA guidance and current GMP rules do not support that conclusion. FDA says sterile products made by aseptic processing must comply with CGMP requirements, and 21 CFR 211.42 requires facilities to have suitable design, space and controls to prevent contamination. What the BioPharm piece argued is narrower: room-level controls should be matched to process reality. (ema.europa.eu) In practice, that means companies may try to achieve protection through closed equipment, isolating interfaces and minimizing interventions, while still maintaining facility and environmental controls required by regulators. That is an inference from the article and current guidance, not a separate regulatory statement. (fda.gov) ### Why does this still resonate years later? EMA’s current GMP materials say manufacturers must meet minimum production standards, and recent agency documents still refer to contamination control strategy and technological advances. BioPharm International itself has continued to publish on evolving cleanroom procedures and sterility challenges, showing the issue remains active as newer therapies and manufacturing formats expand. (biopharminternational.com) The result is that facility designers and manufacturing teams are still weighing the same question the 2011 authors raised: where should contamination control sit in the room, in the equipment or in the process design itself. The next reference points for companies making that decision remain current FDA aseptic-processing guidance, 21 CFR Part 211 and the EU’s Annex 1 framework. (fda.gov) (ema.europa.eu)